MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated.

Autor:in

Smida, Michal; Fece de la Cruz, Ferran; Kerzendorfer, Claudia; Uras, Iris Z; Mair, Barbara; Mazouzi, Abdelghani; Suchankova, Tereza; Konopka, Tomasz; Katz, Amanda M; Paz, Keren; Nagy-Bojarszky, Katalin; Muellner, Markus K; Bago-Horvath, Zsuzsanna; Haura, Eric B; Loizou, Joanna I; Nijman, Sebastian M B

Schlagwörter

Animals; Ataxia Telangiectasia Mutated Proteinsgeneticsmetabolism; Benzamidespharmacology; Cell Line, Tumor; Cell Proliferationdrug effectsgenetics; Diphenylamineanalogs & derivativespharmacology; Humans; Lung Neoplasmsgeneticsmetabolismprevention & control; Mice, Nude; Mutation; Protein Kinase Inhibitorspharmacology; Proto-Oncogene Proteins B-rafgeneticsmetabolism; Pyridonespharmacology; Pyrimidinonespharmacology; RNA Interference; Thiophenespharmacology; Ureaanalogs & derivativespharmacology; Xenograft Model Antitumor Assays; ras Proteinsgeneticsmetabolism

CC Lizenz

CCBY

ISSN/eISSN

2041-1723 -

WoS ID

WOS:000389180300001